London · Delayed Price · Currency is GBP · Price in GBX Hemogenyx Pharmaceuticals Company Description
Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer.
The company’s lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia.
It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures.
Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.
| Country | United Kingdom |
| Founded | 2013 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Vladislav Sandler |
Contact Details
Address: 6 Heddon Street London, W1B 4BT United Kingdom | |
| Website | hemogenyx.com |
Stock Details
| Ticker Symbol | HEMO |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BYX3WZ24 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Vladislav Sandler Ph.D. | Co-Founder, Chief Executive Officer and Director |
| Alexis M. Sandler J.D. | Independent Co-Founder and Non-Executive Director |
| Dr. Koen Van Besien M.D., Ph.D. | Clinical Advisor and Medical Director |
| Ben Harber | Company Secretary |